NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2
Updated: Apr 25, 2022
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
Sponsor:
University of Arkansas
Drug: Velcade, Thalidomide, and Dexamethasone
Drug: Velcade, Melphalan, and Dexamethasone
ClinicalTrials.gov Identifier: NCT00573391
Official Title: A Phase III Study for Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (TT2, UARK 98-026): Bortezomib, Thalidomide and Dexamethasone Versus Bortezomib, Melphalan, and Dexamethasone
First Posted : December 14, 2007
VDTPACE =
Drug: Velcade
Drug: Thalidomide
Drug: Dexamethasone
Drug: Adriamycin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Blood. 2012 Aug